Episodes 181-195 of 260
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
MinuteCE®Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
CME/CEChairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Project Oncology®Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Advancements in GU Cancers: Key Data from AUA 2024
CME/CEAdvancements in GU Cancers: Key Data from AUA 2024
Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC
MinuteCE®Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC
Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC
MinuteCE®Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
MinuteCE®Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models
MinuteCE®Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models
Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC
MinuteCE®Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC
Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices
MinuteCE®Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices
Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC
MinuteCE®Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC
Case by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Driver-Negative Non–Small Cell Lung Cancer
CME/CECase by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Driver-Negative Non–Small Cell Lung Cancer
Current Unmet Needs in the Field of Unresectable HCC
MinuteCE®Current Unmet Needs in the Field of Unresectable HCC
